Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Cadrenal Therapeutics Inc
CVKD
Healthcare
Biotechnology
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients...
with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:CVKD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 10:23am
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD): A Promising Antic
https://beyondspx.com/2024/07/31/cadrenal-therapeutics-inc-nasdaqcvkd-a-promising-anticoagulant-candidate-targeting-unmet-needs/
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 08, 2023 9:00am
New Press Release - Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023
PONTE VEDRA, Fla., Feb. 8, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 06, 2023 9:01am
New Press Release - Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference
PONTE VEDRA, Fla., Feb. 6, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 01, 2023 9:01am
New Press Release - Cadrenal Therapeutics Announces Formation of Scientific Advisory Board
PONTE VEDRA, Fla., Feb. 1, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its Scientific...
read article.
(657)
•••
Iseneschal
X
Comment by
Iseneschal
on Jan 23, 2023 1:39pm
RE:CVKD...... Failure ; )
Worth arepeat !!!!! What a dump !
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 23, 2023 12:04pm
CVKD ...bouncing off bottom?
This was a $5 IPO last July I believe
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 23, 2023 11:46am
CVKD...... Failure ; )
Stops save portfolios Cheers
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 23, 2023 9:42am
CVKD ....in PB mode
Has to hold $5.12 and rally or else done
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 23, 2023 9:34am
CVKD ....early a.m runner
Recent IPO....now halted
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts